Briton Froome cleared by UCI in doping case
Print Edition
Four-time Tour de France winner Chris Froome was cleared by cycling’s world governing body yesterday of any wrongdoing after he tested positive for excessive levels of the asthma drug salbutamol and he is free to race in this year’s event, starting on Saturday.
Froome, 33, had tested positive for excessive levels of salbutamol following a urine sample at last September’s Vuelta a Espana.
“On 28 June 2018, World Anti-Doping Agency (WADA) informed the UCI that it would accept, based on the specific facts of the case, that Mr Froome’s sample results do not constitute an Adverse Analytical Finding,” the International Cycling Union, or UCI, said in a statement. “In light of WADA’s unparalleled access to information and authorship of the salbutamol regime, the UCI has decided, based on WADA’s position, to close the proceedings against Mr Froome.”
The Briton had always denied any wrongdoing and has now been cleared to race in this year’s Tour de France by the organizers who had attempted to prevent the rider from competing while under investigation.
“We started a procedure three weeks ago claiming that Chris Froome taking part in the Tour de France would damage the reputation of the race. But now that the UCI has cleared him there’s no reason for us to prevent him from participating in the race,” Tour de France director Christian Prudhomme said.
Froome welcomed the news which means he can attempt to win a record-equalling fifth Tour when the race gets under way in Noirmoutier.
Team Sky’s Froome can match the record of five titles shared by Jacques Anquetil, Eddy Merckx, Bernard Hinault and Miguel Indurain.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
